Listed

Axil Brands, Inc.: Form 10-Q for the period ended Feb 28, 2025

Filed with the SEC on Apr 8, 2025 and accepted by EDGAR at Apr 8, 2025, 12:01 ET.

Share

Management's discussion and analysis

As filed, 24,923 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

The following Management’s Discussion and Analysis of Financial Condition and Results of Operations should be read in conjunction with, and is qualified in its entirety by, the unaudited consolidated financial statements and related notes thereto included in Item 1 in this Quarterly Report on Form 10-Q and with our audited consolidated financial statements and related notes included in our Annual Report on Form 10-K for the year ended May 31, 2024 filed with the SEC on August 15, 2024. Our Management’s Discussion and Analysis of Financial Condition and Results of Operations contains not only statements that are historical facts, but also statements that are forward-looking.

Although the forward-looking statements in this Quarterly Report on Form 10-Q reflect the good faith judgment of our management, such statements can only be based on facts and factors currently known by them. Consequently, and because forward-looking statements are inherently subject to risks and uncertainties, the actual results and outcomes may differ materially from the results and outcomes discussed in the forward-looking statements. You are urged to carefully review and consider the various disclosures made by us in herein and in our other reports as we attempt to advise interested parties of the risks and factors that may affect our business, financial condition, and results of operations and prospects. Please see “Cautionary Note Regarding Forward-Looking Statements” in this Quarterly Report on Form 10-Q for additional information.

Overview

The Company is engaged in the manufacturing, marketing, sale and distribution of high-tech, innovative hearing and audio enhancement and protection products that provide cutting-edge solutions for people with varied applications across many industries and professional quality hair and skin care products under various trademarks and brands.

The Company has two reportable segments: hair care and skin care, and hearing enhancement and protection.

Through our hearing enhancement and protection segment, we design, innovate, engineer, manufacture, market and service specialized systems in hearing enhancement, hearing protection, wireless audio, and communication. Through our hair care and skin care segment, we manufacture, market, sell, and distribute professional quality hair and skin care products.

The Company’s overall business strategy is to establish market awareness of our products through our direct-to-consumer campaigns. The Company’s strategy centers on driving growth by expanding market share within existing channels and developing new ones through both online and traditional platforms. The Company’s primary focus is optimizing its e-commerce strategies, building sales teams to meet the needs of distribution channels, and enhancing value through strategic partnerships. The Company is also working to expand its offline retail presence and enter into new international markets. We believe the increase in awareness will allow us to increase distribution and gain customers through our distribution partners’ retail establishments, with the goal of helping us achieve growth in market share and diversify our sales channels; however, we cannot provide any assurances that such increases will occur, or that we will realize the anticipated benefits of our actions.

In addition, the Company is exploring options for its hair care and skin care business, which could result in the divestiture of such business. Any such divestiture may not occur in a timely manner, or at all, and the Company may not be able to realize any benefits from any strategic actions it may engage in with respect to its hair care and skin care business.

Business Update

In light of recent changes to U.S. trade policy, including the imposition of elevated tariffs on certain imported goods, AXIL has accelerated its previously initiated supply chain transition strategy. While we have historically relied on international suppliers for the majority of our manufacturing operations, we began proactively evaluating alternative strategies in anticipation of these risks.

To strengthen our long-term operational flexibility and reduce exposure to geopolitical volatility, we have initiated the relocation of senior manufacturing leadership to the United States. This relocation is part of a broader initiative to establish domestic manufacturing capabilities, including the setup of new production facilities. These efforts are expected to improve both cost stability and responsiveness to customer demand over time.

Although we anticipate some increase in product costs in the near term as a result of these tariffs, we believe our current inventory levels and ongoing mitigation strategies position us to navigate this period with minimal disruption. We are continuing to evaluate a range of strategic options to manage these cost pressures, including supply chain optimization, pricing strategies, and sourcing adjustments. We believe we will be able to adapt to the evolving trade environment and believe the actions we are taking now will enhance our resilience and competitiveness in the medium and long term.

  • 2-

Results of Operations

Our results of operations are summarized below.

Three months ended February 28, 2025 February 29, 2024 Nine months ended February 28, 2025 February 29, 2024
Sales, net $6,922,367 $6,469,343 $20,506,213 $20,997,289
Cost of sales 1,955,939 1,845,017 5,888,090 5,467,458
Gross profit 4,966,428 4,624,326 14,618,123 15,529,831
Total operating expenses 4,383,319 4,728,205 13,502,845 14,196,041
Income (loss) from operations 583,109 (103,879) 1,115,278 1,333,790
Net income after tax $576,662 $781,091 $1,100,563 $1,953,618

We calculate EBITDA by taking net income calculated in accordance with accounting principles generally accepted in the United States (“GAAP”), and adjusting for income taxes, interest income or expense, and depreciation and amortization. We calculate adjusted EBITDA as EBITDA, further adjusted for stock-based compensation. Adjusted EBITDA is also presented as a percentage of revenue, which is calculated by dividing the non-GAAP Adjusted EBITDA for a period by revenue for the same period. Other companies may calculate EBITDA and adjusted EBITDA differently, limiting the usefulness of these measures for comparative purposes. We believe that these non-GAAP measures of financial results provide useful information regarding certain financial and business trends relating to our financial condition and results of operations, and management considers EBITDA and adjusted EBITDA important indicators in evaluating our business on a consistent basis across various periods for trend analyses. These non-GAAP financial measures exclude significant expenses and income that are required by GAAP to be recorded in our financial statements and are subject to inherent limitations as they reflect the exercise of judgments by management about which expenses and income are excluded or included in determining these non-GAAP financial measures. Investors should review the reconciliation of these non-GAAP financial measures to the comparable GAAP financial measure included below. Investors should not rely on any single financial measure to evaluate our business.

For the Three Months Ended February 28, 2025 February 29, 2024 For the Nine Months Ended February 28, 2025 February 29, 2024
Net income (GAAP) $576,662 $781,091 $1,100,563 $1,953,618
Provision (benefit) for income taxes 53,085 (827,436) 120,335 (397,054)
Interest income, net (42,920) (51,420) (97,595) (124,454)
Depreciation and amortization 45,666 27,614 93,001 83,634
Total EBITDA (Non-GAAP) 632,493 (70,151) 1,216,304 1,515,744
Adjustments:
Stock-based compensation 258,053 59,099 860,517 161,314
Total Adjusted EBTIDA (Non-GAAP) $890,546 $(11,052) $2,076,821 $1,677,058
Sales, net (GAAP) $6,922,367 $6,469,343 $20,506,213 $20,997,289
Adjusted EBITDA as a percentage of Sales, net (Non-GAAP) 12.9% (0.2)% 10.1% 8.0%
  • 3-

For the Three Months Ended February 28, 2025 Compared to the Three Months Ended February 29, 2024

Net sales for the three months ended February 28, 2025 and February 29, 2024 were $6,922,367 and $6,469,343, respectively. Net sales for the three months ended February 28, 2025 increased by $453,024 or 7.0%, as compared to the three months ended February 29, 2024. The increase in sales was primarily attributable to an increase in direct-to-consumer sales that was significantly affected by the shift of post-Thanksgiving holidays falling in the third quarter in fiscal year 2025. Furthermore, we strengthened our distribution channels of AXIL products, expanded our presence in new geographic regions, and increased distributor sales of our hair and skin care products.

For the three months ended February 28, 2025, the overall cost of sales increased by $110,922 or 6.0%, as compared to the three months ended February 29, 2024, which was primarily due to the strengthening of our distribution channels in both segments of our business. Cost of sales as a percentage of net revenues for the three months ended February 28, 2025 was 28.3% as compared to 28.5% for the three months ended February 29, 2024.

Gross profit for the three months ended February 28, 2025 and February 29, 2024 was $4,966,428 and $4,624,326, respectively. Gross profit as a percentage of sales for the three months ended February 28, 2025 was 71.7%, as compared to 71.5% for the three months ended February 29, 2024.

Operating expenses consisted of marketing and selling expenses, compensation and related taxes, professional and consulting fees, and general and administrative costs. Operating expenses decreased by $344,886 or 7.3% from $4,728,205 in the three months ended February 29, 2024 to $4,383,319 in the three months ended February 28, 2025. Operating expense as a percentage of revenue for the three months ended February 28, 2025 was 63.3% compared 73.1% for the three months ended February 29, 2024. Included in operating expenses were non-cash stock-based compensation of $258,053 and $59,099 in the three months ended February 28, 2025 and three months ended February 29, 2024, respectively. The decrease in operating expenses related primarily to lower advertising costs, as we move to a more targeted and efficient approach of advertising for direct-to-consumer sales channels and improve reliance on our distribution channels. During the three months ended February 28, 2025, we incurred approximately $195,000 in consulting fees to support our expansion into new geographic markets, compared to $0 for the same period in 2024. Of this amount, approximately $116,000 was related to stock-based compensation. We have also incurred additional costs related to new product lines. We believe we have not yet realized the anticipated benefits from our recent efforts to expand into new geographic markets and product lines.

Income from operations for the three months ended February 28, 2025 was $583,109 compared to a loss from operations of $103,879 for the three months ended February 29, 2024. The increase in income from operations of $686,988 was primarily related to increased sales in both our direct-to-consumer channels as well as our distribution channels, partially offset by an increase in stock-based compensation.

For the three months ended February 28, 2025 provision for income taxes was $53,085. For the three months ended February 29, 2024, we had an income tax benefit of $827,436.

As a result of the above, we reported a net income of $576,662 and a net income of $781,091 for the three months ended February 28, 2025 and February 29, 2024, respectively.

Adjusted EBITDA increased by $901,598 to $890,546 for the three months ended February 28, 2025 from an Adjusted EBITDA loss of $11,052 for the three months ended February 29, 2024. The increase of Adjusted EBITDA related to increased sales in both our direct-to-consumer channels as well as our distribution channels. Adjusted EBITDA as a percentage of sales, net for the three months ended February 28, 2025 and February 29, 2024, was 12.9% and (0.2)%, respectively.

For the Nine Months Ended February 28, 2025 Compared to the Nine Months Ended February 29, 2024

Net sales for the nine months ended February 28, 2025 and nine months ended February 29, 2024 were $20,506,213 and $20,997,289, respectively. Net sales for the nine months ended February 28, 2025 decreased by $491,076 or 2.3%, as compared to the nine months ended February 29, 2024. This decrease was primarily due to reduced advertising expenditure which adversely affected direct to consumer sales in the first and second quarters of the fiscal year offset by the strong performance of the third quarter.

  • 4-

For the nine months ended February 28, 2025, the overall cost of sales increased by $420,632 or 7.7%, as compared to the nine months ended February 29, 2024. Cost of sales as a percentage of net revenues for the nine months ended February 28, 2025 was 28.7% as compared to 26.0% for the three months ended February 29, 2024. The increase in cost of sales, as a percentage of sales, was primarily attributable to an increase in sales to distributors in both our hair and skin care products and our hearing enhancement and protection segment, bearing lower margins.

Gross profit for the nine months ended February 28, 2025 and February 29, 2024 was $14,618,123 and $15,529,831, respectively. Gross profit as a percentage of sales for the nine months ended February 28, 2025 was 71.3%, as compared to 74.0% for the nine months ended February 29, 2024. The decrease in the gross profit margin for the nine months ended February 28, 2025 was primarily attributable to an increase in cost of sales as a percentage of revenue, and an increase in discounts as a percentage of revenue.

Operating expenses consisted of marketing and selling expenses, compensation and related taxes, professional and consulting fees, and general and administrative costs. Operating expenses decreased by $693,196 or 4.9% from $14,196,041 in the nine months ended February 29, 2024 to $13,502,845 in the nine months ended February 28, 2025. Operating expenses as a percentage of net revenues for the nine months ended February 28, 2025 was 65.8% compared to 67.6% for the nine months ended February 29, 2024. Included in operating expenses were non-cash stock-based compensation of $860,517 and $161,314 in the nine months ended February 28, 2025 and February 29, 2024, respectively. The decrease in operating expenses related primarily to a net decrease in advertising expenses, and a forgiveness of account payable amounting to approximately $220,000 partially offset by an increase of stock-based compensation of $699,203 and increased professional and consulting fees. During the nine months ended February 28, 2025, we incurred approximately $395,000 in consulting fees to support our expansion into new geographic markets, compared to $0 for the same period in 2024. Of this amount, approximately $195,000 was related to stock-based compensation. We have also incurred additional costs related to new product lines. We believe we have not yet realized the anticipated benefits from our recent efforts to expand into new geographic markets and product lines.

Income from operations for the nine months ended February 28, 2025, was $1,115,278 compared to income of $1,333,790 for the nine months ended February 29, 2024. The decrease in income from operations of $218,512 or 16.4% was primarily related to an increase in our non-cash stock-based compensation.

For the nine months ended February 28, 2025, provision for income tax expense was $120,335. For the nine months ended February 29, 2024, income tax benefit was $397,054.

As a result of the above, and a gain on settlement of debt of approximately $79,000 in the prior year period that did not recur in the current period, we reported a net income of $1,100,563 and $1,953,618 for the nine months ended February 28, 2025 and February 29, 2024, respectively.

Adjusted EBITDA increased by $399,763, or 23.8% from $1,677,058 for the nine months ended February 29, 2024 to $2,076,821 for the nine months ended February 28, 2025. Adjusted EBITDA as a percentage of sales, net for the nine months ended February 28, 2025 and February 29, 2024 was 10.1% and 8.0%, respectively. The increase was primarily due to a strong performance of the third quarter in fiscal year 2025, a forgiveness of account payable amounting to approximately $220,000 and a decrease in advertising expenses.

Liquidity and Capital Resources

We are currently engaged in product sales and development. Although we earned net income and have cash provided by operations for the nine months ended February 28, 2025, we have incurred operating losses in the past. We currently expect to earn net income and positive cash flows from operations during the current fiscal year ending May 31, 2025. We believe our current cash balances, coupled with anticipated cash flow from operating activities, will be sufficient to meet our working capital requirements for at least one year from the date of issuance of the accompanying unaudited consolidated financial statements. We intend to continue to control our cash expenses as a percentage of expected revenue on an annual basis and thus may use our cash balances in the short-term to invest in revenue growth. As a result of the acquisition of AXIL & Associated Brands’ assets in June 2022, we have generated and expect we will continue to generate sufficient cash for our operational needs, including any required debt payments, for at least one year from the date of issuance of the accompanying unaudited consolidated financial statements. Management is focused on growing the Company’s existing product lines and introducing new products, as well as expanding its customer base, to increase its revenues. The Company cannot give assurance that it can increase its cash balances or limit its cash consumption and thus maintain sufficient cash balances for its planned operations or future acquisitions. Future business demands may lead to cash utilization at levels greater than recently experienced. The Company cannot provide any assurance that it will be able to raise additional capital or obtain necessary financing on acceptable terms, or at all. Subject to the foregoing, management believes that the Company has sufficient capital and liquidity to fund its operations for at least one year from the date of issuance of the accompanying unaudited consolidated financial statements.

  • 5-

Cash Flows

Operating Activities

Net cash provided by operating activities for the nine months ended February 28, 2025, was $1,734,230, compared to $339,323 for the nine months ended February 29, 2024. This improvement primarily resulted from our strategic decision to increase inventory levels as of May 31, 2024 to accommodate new product variations and packaging aimed at expanding into new markets. Inventory sold during the nine months ended February 28, 2025 contributed positively to cash flows. We also negotiated a forgiveness of accounts payable during the nine months ended February 28, 2025, resulting in an improvement of operating cash flows of approximately $220,000 offset by timing of net changes in operating assets and liabilities excluding inventory.

Investing Activities

Net cash flows used in investing activities for the nine months ended February 28, 2025 was $255,778 due to the purchase of intangibles and property and equipment for the Company’s business. For the nine months ended February 29, 2024, net cash flows used in investing activities were $80,192, attributable to the cash used in the purchase of property and equipment primarily relating to our expansion into new product lines.

Financing Activities

Net cash flows provided by financing activities for the nine months ended February 28, 2025 was $11,142, and were from advances made from a related party of $16,778 partially offset by a repayment of the note payable of $5,636. Net cash flows used in financing activities for the nine months ended February 29, 2024 were $204,246 primarily related to the repayment of note payable of $25,438 and payments to our related party of $176,608.

As of February 28, 2025, we had a secured Economic Injury Disaster Loan outstanding, administered pursuant to the CARES Act in the principal amount of $140,958, with a maturity date of May 18, 2050. The Company continues to pay interest and principal on the loan.

We are dependent on our product sales to fund our operations and may require additional capital in the future, such as pursuant to the sale of additional common or preferred stock or of debt securities or entering into credit agreements or other borrowing arrangements with institutions or private individuals, to maintain operations, which may not be available on favorable terms, or at all, and could require us to sell certain assets or discontinue or curtail our operations. If the current equity and credit markets deteriorate, it may make any necessary debt or equity financing more difficult to obtain, more costly and more dilutive. Our officers and directors have made no written commitments with respect to providing a source of liquidity in the form of cash advances, loans, and/or financial guarantees. We do not have any plans to seek additional financing at this time and anticipate that our existing cash equivalents and cash provided by operations will be sufficient to meet our working capital requirements. However, if the need arises for additional cash, there can be no assurance that we will be able to raise the capital we need for our operations on favorable terms, or at all. We may not be able to obtain additional capital or generate sufficient revenues to fund our operations. Failure to secure any necessary financing in a timely manner and on favorable terms could have a material adverse effect on our growth strategy, financial performance and stock price and could require us to delay or abandon our business plans. If we are unsuccessful at raising sufficient funds, for whatever reason, to fund our operations, we may be forced to cease operations. If we fail to raise funds, we expect that we will be required to seek protection from creditors under applicable bankruptcy laws.

Off-Balance Sheet Arrangements

As of February 28, 2025, we did not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results or operations, liquidity, capital expenditures or capital resources that is material to investors.

Critical Accounting Policies

The preparation of condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires us to make a number of estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements. Such estimates and assumptions affect the reported amounts of expenses during the reporting period. On an ongoing basis, we evaluate estimates and assumptions based upon historical experience and various other factors and circumstances. We believe our estimates and assumptions are reasonable in the circumstances; however, actual results may differ from these estimates under different future conditions.

We believe that the estimates and assumptions that are most important to the portrayal of our financial condition and results of operations, in that they require the most difficult, subjective or complex judgments, form the basis for the accounting policies deemed to be most critical to us. These critical accounting policies relate to revenue recognition, impairment of intangible assets and long-lived assets, inventory, stock compensation, and evaluation of contingencies. We believe estimates and assumptions related to these critical accounting policies are appropriate under the circumstances; however, should future events or occurrences result in unanticipated consequences, there could be a material impact on our future financial condition or results of operations.

See the footnotes to our unaudited consolidated financial statements for the three and nine months ended February 28, 2025, included with this Quarterly Report on Form 10-Q for additional discussion of our critical accounting policies and use of estimates.

  • 6-

Controls and procedures

As filed, 1,514 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Disclosure Controls and Procedures

We maintain “disclosure controls and procedures,” as such term is defined in Rules 13a-15(e) or 15d-15(e) under the Exchange Act, that are designed to ensure that information required to be disclosed in our Exchange Act reports is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer (“CEO”) and Principal Executive Officer, and Chief Financial Officer (“CFO”) and Principal Financial and Accounting Officer, as appropriate, to allow timely decisions regarding required disclosure. We conducted an evaluation, under the supervision and with the participation of our CEO and CFO, of the effectiveness of the design and operation of our disclosure controls and procedures as of February 28, 2025. Based on this evaluation of disclosure controls and procedures as of February 28, 2025, our CEO and CFO concluded that our disclosure controls and procedures were effective.

Changes in Internal Control over Financial Reporting

There have been no changes in our internal control over financial reporting identified in connection with the evaluation required by Rules 13a-15(d) or 15d-15(d) under the Exchange Act that occurred during the fiscal quarter ended February 28, 2025 that have materially affected or are reasonably likely to materially affect our internal control over financial reporting.

  • 7-

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2025-02-28. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2024-12-01 to 2025-02-28$6.9mus-gaap:Revenues
Revenue9 months2024-06-01 to 2025-02-28$20.5mus-gaap:Revenues
Cost of revenue3 months2024-12-01 to 2025-02-28$2.0mus-gaap:CostOfGoodsAndServicesSold
Cost of revenue9 months2024-06-01 to 2025-02-28$5.9mus-gaap:CostOfGoodsAndServicesSold
Gross profit3 months2024-12-01 to 2025-02-28$5.0mus-gaap:GrossProfit
Gross profit9 months2024-06-01 to 2025-02-28$14.6mus-gaap:GrossProfit
Operating income3 months2024-12-01 to 2025-02-28$583.1kus-gaap:OperatingIncomeLoss
Operating income9 months2024-06-01 to 2025-02-28$1.1mus-gaap:OperatingIncomeLoss
Interest expense3 months2024-12-01 to 2025-02-28$1.3kus-gaap:InterestExpenseNonoperating
Interest expense9 months2024-06-01 to 2025-02-28$2.6kus-gaap:InterestExpenseNonoperating
Income tax3 months2024-12-01 to 2025-02-28$53.1kus-gaap:IncomeTaxExpenseBenefit
Income tax9 months2024-06-01 to 2025-02-28$120.3kus-gaap:IncomeTaxExpenseBenefit
Net income3 months2024-12-01 to 2025-02-28$576.7kus-gaap:NetIncomeLoss
Net income9 months2024-06-01 to 2025-02-28$1.1mus-gaap:NetIncomeLoss
Diluted EPS3 months2024-12-01 to 2025-02-28$0.07us-gaap:EarningsPerShareDiluted
Diluted EPS9 months2024-06-01 to 2025-02-28$0.13us-gaap:EarningsPerShareDiluted
Basic EPS3 months2024-12-01 to 2025-02-28$0.09us-gaap:EarningsPerShareBasic
Basic EPS9 months2024-06-01 to 2025-02-28$0.17us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2024-12-01 to 2025-02-288,202,402 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Diluted shares (weighted)9 months2024-06-01 to 2025-02-288,196,605 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow9 months2024-06-01 to 2025-02-28$1.7mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure3 months2024-12-01 to 2025-02-28$148.2kus-gaap:PaymentsToAcquireProductiveAssets
Capital expenditure9 months2024-06-01 to 2025-02-28$154.1kus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2025-02-28$4.7mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2025-02-28$9.3mus-gaap:AssetsCurrent
Total assetsAt period end2025-02-28$13.0mus-gaap:Assets
Current liabilitiesAt period end2025-02-28$2.4mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2025-02-28$3.3mus-gaap:Liabilities
Long-term debtAt period end2025-02-28$141.0kus-gaap:LongTermDebt
Shareholders' equityAt period end2025-02-28$9.7mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001520138-25-000113. Last ingested by Listed: Oct 24, 2026, 15:15 ET. Listed shows no prices and gives no investment advice.